Zim Laboratories Limited, a pharmaceutical company specializing in innovative drug delivery solutions, has announced a postal ballot to seek shareholder approval for the re-appointment of two of its Whole-time Directors, Mr. Niraj Dhadiwal and Mr. Prakash Sapkal, for an additional two-year term.

Key Details of the Postal Ballot

• Re-appointment Period: October 1, 2025, to September 30, 2027
• E-voting Period: October 15 to November 13, 2025
• Results Announcement: By November 15, 2025

Proposed Remuneration Package

The company has proposed the following remuneration structure for both directors:

Director Profiles

Mr. Niraj Dhadiwal

• Current Role: Director - Business Development
• Experience: Over 30 years in the pharmaceutical sector
• Focus: Business development and marketing functions
• Vision: Global presence with innovative and differentiated products

Mr. Prakash Sapkal

• Current Role: Director - Operations
• Experience: More than 30 years in the pharmaceutical industry
• Expertise: Key operations and team management
• Contribution: Instrumental in bringing ZIM Labs' vision to life

Both directors have been with Zim Laboratories for nearly three decades, rising through the ranks to their current positions. Their extensive experience and contributions have been pivotal to the company's growth and expansion strategies.

Voting Process

The company has appointed Ms. Roshni Jethani as the scrutinizer for the postal ballot process. Shareholders can cast their votes through remote e-voting, with the results to be announced within two days of the conclusion of the voting period.

Company's Strategic Direction

Zim Laboratories is currently focusing on expanding its presence in regulated markets such as the EU. The company is investing in product development and infrastructure upgrades to meet the requirements of these new markets. While this transition period may impact short-term profitability, the management anticipates improved results in the long run as new high-potential products gain registration and market traction.

The re-appointment of Mr. Dhadiwal and Mr. Sapkal is seen as a move to ensure continuity in leadership as the company navigates this crucial phase of expansion and development in regulated markets.

Shareholders are encouraged to review the detailed postal ballot notice and cast their votes before the e-voting deadline.

Zim Laboratories Limited, a prominent player in the pharmaceutical industry, has announced the reappointment of two key executives to its leadership team. The company's Board of Directors has approved the extension of Mr. Niraj Dhadiwal and Mr. Prakash Sapkal as Whole-Time Directors for an additional two-year term, commencing October 1, 2025.

Board Decision and Approval Process

The decision was made during a board meeting held on September 19, 2025, following recommendations from the Nomination and Remuneration Committee. Both reappointments are subject to shareholder approval, highlighting the company's commitment to corporate governance and transparency.

Mr. Niraj Dhadiwal: A Veteran in Business Development

Mr. Niraj Dhadiwal, who will continue as Director – Business Development, brings nearly three decades of experience with Zim Laboratories to his role. His reappointment underscores the company's recognition of his significant contributions:

• Educational Background: Pharmacy graduate with a diploma in business management
• Career Progression: Started as a production officer in 1991, rising through the ranks to his current directorial position
• Key Responsibilities: Oversees business development and marketing functions
• Notable Achievements: Played a crucial role in the company's export development, demonstrating strong business acumen and technical knowledge

Mr. Prakash Sapkal: Operations Expert

Mr. Prakash Sapkal, reappointed as a Whole-Time Director, has been an integral part of Zim Laboratories for 26 years. His continued leadership is expected to drive operational excellence:

• Educational Background: Pharmacy graduate with an MBA
• Career Journey: Began as an Assistant Chemist and progressed through various operational roles
• Key Positions Held: Production Supervisor, Production Manager, and Vice President – Operations
• Significant Contribution: Instrumental in building a team that has brought Zim Labs' vision to fruition

Corporate Governance and Compliance

Zim Laboratories has confirmed that both Mr. Dhadiwal and Mr. Sapkal are not debarred from holding directorial positions by any regulatory authority. Additionally, the company has disclosed that neither director is related to any other board members, ensuring independence in decision-making processes.

The reappointments of these seasoned professionals signal Zim Laboratories' commitment to maintaining stability in its leadership while leveraging their extensive experience and industry knowledge. As the company moves forward, the extended tenure of these directors is likely to play a crucial role in shaping its strategic direction and operational efficiency in the competitive pharmaceutical landscape.